Health ❯ Healthcare ❯ Obesity

Weight Management

Medications GLP-1 Receptor Agonists GLP-1 Drugs Dietary Medications Semaglutide Weight Loss Medications Dietary Interventions Mounjaro Prescription Medications GLP-1 Medications Medication Options Hormonal Treatments Weight Loss Treatments Medication Management Weight Loss Drugs Semaglutide for Weight Loss Weight-loss Injections Clinical Trials Oral Medications Medication Effects Diet and Exercise Weight Loss Injections Appetite Control Tirzepatide Drug Comparison BMI Guidelines Mounjaro for Weight Loss Treatment Options NHS Treatments Behavioral Interventions Weight Regain BMI Calculation GLP-1/GIP Dual Agonists GLP-1 Receptor Alternatives Dietary Supplements CagriSema Exercise Obesity-related Conditions Pharmaceuticals Medications for Weight Loss Weight Loss Programs Slimming Injections Semaglutide Trials Clinical Outcomes Injections Behavioral Programs Menopause Patient Access Anti-obesity Injections GLP-1 Agonists Tirzepatide for Obesity Drug Treatments Ozempic Metabolic Health Hormonal Imbalance BMI Calculations Belly Fat Reduction Wegovy Weight-loss Medications Belly Fat Gastric Bypass Surgery Patient Support GLP-1 Drugs for Obesity Compounded Medications Diet and Lifestyle Changes Incretin-based Therapies Deprescription Strategies Physical Activity Weight Loss Alternatives GLP-1 for Weight Loss BMI GLP-1 and GIP Analogs Pharmaceutical Treatments Duodenal Mucosal Resurfacing Semaglutide Effects Therapeutic Efficacy GLP-1 Management Program Weight-related Co-morbidities Bariatric Procedures NHS Rollout Muscle Preservation Patient Experiences Public Health Fat Jabs Abdominal Obesity Lifestyle Changes Guidelines GLP-1 Therapies Medication Efficacy Medication Prescription Guidelines Weight-loss Drugs Medication Pricing GLP-1 Treatment Dietary Strategies GLP-1 and Obesity Diabetes Management Anti-Obesity Medications

Wearable Data Show People Move Less After Starting GLP‑1 Weight‑Loss Drugs

ENDO 2026 presentations link the activity drop to greater risk of lean muscle loss and call for prescribing structured exercise with GLP‑1 therapy.

Major U.S. Societies Publish First Clinical Guideline for Cardiovascular‑Kidney‑Metabolic Syndrome

Roche Stops Phase 3 for Acmopatide After Positive Phase 2 in Type 1 Diabetes

CHMP Recommends Adding Oral Wegovy Tablets to EU Approval

New Risk Score Predicts 10-Year Risk for 18 Obesity-Linked Diseases

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

Trial Hints ‘Gut Reset’ May Slow Weight Regain After Stopping GLP‑1 Drugs

Studies Link GLP-1 Drugs to Lower Addiction and Overdose Risks

Heart Risks Rebound After GLP-1 Breaks, New Data Show Continuous Use Is Safest

India Braces for 50+ Semaglutide Generics as Patent Expires Friday

Most Weight Lost on GLP-1 Drugs Returns After Stopping, New Analysis Finds

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

Lilly Combo of Zepbound and Taltz Tops Taltz Alone in Late-Stage Psoriasis Trials

GLP-1 Weight-Loss Boom Triggers Safety Warnings and New Oversight

CagriSema Beats Semaglutide on HbA1c and Weight at 68 Weeks in Type 2 Diabetes Trial

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

Novo Nordisk Files FDA Application for Weekly CagriSema Obesity Shot as GLP-1 Competition Intensifies

Lilly’s Triple-Agonist Retatrutide Shows Major Phase 3 Weight Loss as Grey-Market Use Prompts Warning

EMA Panel Backs Higher 7.2 mg Wegovy Dose for Obesity

CHMP Backs Expanded EU Use of Mounjaro for Diabetes in Patients 10+ and Adult Weight Management